Rachel Gollub

Biography
Rachel Gollub founded her current company to bring together patient medical history, social determinants of health, and genomic data to bring secure precision medicine to patients everywhere. A Silicon Valley inventor and entrepreneur with a degree from Caltech, she started her career on the team inventing the Java language, later moving to Stanford University to design and build the Stanford Digital Repository. Since then, she has been founding companies to leverage the latest technologies. Most recently, she left a position as CTO of the UnitedHealthcare Technology Employer Individual division to leverage her AI and machine learning background to build a startup at the heart of precision medicine.

AI and Data Sciences Showcase:
PointHealth AI
PointHealth AI brings together medical history, social determinants of health, and genomics to bring better courses of treatment to patients. We give providers on-the-spot recommendations from our data analyses to help patients at the point of diagnosis.

Keith Booher

Biography
Keith Booher has been involved in the biotech sector for 15 years taking on various scientific, business development, and leadership roles. In his current position at Zymo Research, Keith leads the professional research services team, which primarily utilizes NGS technology to answer questions in the field of genomics especially, microbiome, epigenome, and transcriptome focused analysis. In addition, Keith is the Principal Investigator on over $12 million in research grants and contracts from various federal and local entities. Keith is particularly interested in multi-omics approaches that utilize advanced sample prep, cutting edge sequencing, and Artificial Intelligence or Machine Learning tools to help solve the most challenging problems in molecular biology.

AI and Data Sciences Showcase:
Zymo
Zymo Research, a privately owned biotech company founded in 1994, is a global leader in molecular tools for life sciences. Driven by the principle "The Beauty of Science is to Make Things Simple," Zymo is dedicated to developing innovative solutions that address complex scientific challenges.

Arnout Van Hyfte

Biography
Arnout Van Hyftes journey with BioStrand, now a subsidiary of IPA (ImmunoPrecise Antibodies), began in 2019 as a key member of the founding team. He has played a pivotal role in shaping the company's commercial strategies, setting the stage for its remarkable growth, and building a robust infrastructure that forms the very foundation of BioStrand's operations. Arnout oversees the development team, ensuring their seamless coordination and fostering a culture of innovation. His leadership extends to crafting effective sales and marketing strategies, as well as engaging with the market to cultivate meaningful relationships.

---

Talk
-
-

AI and Data Sciences Showcase:
MindWalk
MindWalk is a global biologics discovery company integrating bio-native intelligence, deep data, and advanced lab research in a customizable ecosystem. We partner with biotech and pharma to accelerate therapeutic, anti-drug, diagnostic, peptide, and vaccine programs with depth, clarity, and speed.

Anastasia Rigas

Biography
Anastasia Rigas leads Heteron Biotechnologies in developing a clinical-stage breath diagnostics platform that leverages advanced machine learning to transform complex breath profilescontaining thousands of gases and VOCsinto precise, multi-indication diagnostics. Under her leadership, Heterons multidisciplinary team has applied and rigorously tested various models on proprietary datasets, achieving exceptionally high classification accuracy. This builds on prior peer-reviewed expertise now integrated in-house, positioning the platform to detect H. pylori for gastric cancer prevention, stratify metabolic syndrome risk, and enable future hepatic and performance health applications. The technology is advancing under FDA CDRH oversight with pivotal trials in preparation and secured by global PCT filings covering hardware, software, and disease-specific biomarkers. Passionate about shifting healthcare from reactive intervention to AI-driven prevention, Anastasia coordinates regulatory strategy, multi-center clinical design, and strategic partnerships to establish breath-based machine learning diagnostics as a new paradigm in accessible precision medicine

---

Talk
AI Breath Diagnostics for Early Disease Detection
Heterons multi-gas breath platform integrates proprietary machine learning to classify complex VOC profiles, enabling accurate point-of-care diagnosis of H. pylori, Celiac and metabolic syndrome. Advancing under FDA CDRH oversight with global PCT protection, it delivers scalable, reimbursable AI-driven diagnostics that identify earlier-stage disease, improving outcomes through timely, informed clinical intervention.

AI and Data Sciences Showcase:
Heteron BIotechnologies,
Heteron is a clinical-stage diagnostics company advancing a multi-gas breath analysis platform that uses proprietary machine learning to deliver precise, multi-indication detection from complex breath samples. The technology targets scalable, reimbursable screening for gastric cancer prevention, metabolic syndrome, Celiac Disease and broader preventive care.

Hugo Lam

Biography
Hugo Lam, Ph.D., is a Distinguished Engineer and Uber Tech Lead at Genentech, where he guides strategy in advanced data engineering and AI to accelerate scientific innovation. His work focuses on building scalable, FAIR-compliant data ecosystems that are AI-ready and empower cross-functional collaboration, accelerating discovery and enterprise decision-making.Before returning to Genentech, Dr. Lam founded and led HypaHub, directing bioinformatics and software engineering programs that advanced AI- and data-driven diagnostics and therapeutics. The company gained recognition from angels, venture capital, and Y Combinator.Earlier in his career, Dr. Lam led bioinformatics efforts at Roche, shaping data-science strategy and driving informatics research that contributed to next-generation healthcare product development, including work published in Nature Communications. His experience also spans 23andMe, Personalis, and Bina Technologies (acquired by Roche), giving him broad expertise across genomics, computational biology, and large-scale data systems.

---

Talk
Systems Integration for Drug Discovery and AI
This talk highlights how a unified, AI-ready Data Ecosystem accelerates scientific discovery by integrating data, automation, and adaptive intelligent interfaces. By simplifying access to complex research assets and enabling more dynamic, insight-driven workflows, we empower RD teams to innovate faster and make more informed decisions across the discovery lifecycle.

AI and Data Sciences Showcase:
Genentech

Mark Kiel

Biography
Dr. Mark Kiel completed his M.D., Ph.D., and Molecular Genetic Pathology Fellowship at the University of Michigan, where his research focused on stem cell biology, genomic profiling of hematopoietic malignancies, and clinical bioinformatics. He is the founder and chief scientific officer at Genomenon, a genomic intelligence company, where he oversees the company's scientific direction and product development. Mark founded Genomenon in 2014 to address the challenge of connecting researchers with evidence in the genomic literature to help diagnose and treat patients with genetic diseases and cancer.

---

Talk
Unlocking the Power of Literature-Derived Real-World Evidence
The biomedical literature reflects decades of global clinical practice and millions of highly detailed patient records. Especially for rare or complex indications, where traditional sources of RWE may lack coverage, this evidence can fill critical gaps. We reveal how literature-derived RWE can complement other sources and optimize precision medicine programs in inherited disease and oncology.

AI and Data Sciences Showcase:
Genomenon
Genomenon provides genomic intelligence for clinical diagnostics and precision medicine development. We simplify complex genetic data into actionable insights.

Clifford Ried

Biography
Dr. Clifford Reid has over 30 years of experience in leading start-up and growth companies that commercialize important new technologies. Dr. Reid was the founding CEO of Travera, a spinout of MIT that developed a novel live-cell cancer therapy selection test. Prior to founding Travera, he was the founding Executive Chairman of Genos Research, a consumer genomics company that developed a marketplace for genomics research data. Dr. Reid was the founding Chairman and Chief Executive Officer of Complete Genomics (CGI), a leading developer of whole human genome DNA sequencing technologies. He took the company public (GNOM: NASDAQ) and led it through its acquisition by BGI. Prior to CGI he founded two enterprise software companies, Eloquent (ELOQ: NASDAQ, an internet video company) which was acquired by Open Text, and Verity (VRTY: NASDAQ, an enterprise search engine company) which was ultimately acquired by Hewlett-Packard.Dr. Reid is on the Visiting Committee of the Biological Engineering Department at the Massachusetts Institute of Technology (MIT) and is a member of the MIT Corporation Development Committee. He is a scientific advisor to NGD, a bacterial genomics company. He earned a BS in Physics from MIT, an MBA from the Harvard Business School, and a PhD in Management Science and Engineering from Stanford University.

AI and Data Sciences Showcase:
Cancer Commons

Boris Khazin

Biography
Seasoned executive and board advisor with over 20 years of leadership experience in governance, risk, compliance (GRC), cybersecurity, and AI-driven digital resilience.Has a proven track record of guiding global enterprises and fintech startups through complex regulatory landscapes, technology transformation, and operational scaling.Successfully built and scaled multimillion-dollar GRC practices, launched award-winning Financial products, and pioneered AI-based compliance solutions in collaboration with industry leaders like Google and Microsoft.

---

Talk
Diagnosis of Low-Grade Central Osteosarcoma
This presentation showcases a clinical case of low-grade central osteosarcoma often misdiagnosed as fibrous dysplasia. Using a ResNet-101 convolutional neural network for automated mitosis detection, AI accurately identified malignancy (up to 99% probability), aligning with expert diagnoses. The study highlights AIs promise to improve accuracy, reproducibility, and confidence in complex pathology.

AI and Data Sciences Showcase:
MegAITex
MegAITex is an AI-driven medical technology company developing deep learning solutions to enhance diagnostic accuracy and efficiency in pathology. Its platform leverages advanced neural networks to detect early signs of cancer and other diseases from digitized biopsy images, reducing diagnostic errors and enabling faster, more reliable clinical decisions.

Rowan Chapman

Biography
Rowan is a co-founder of BEVC an early stage VC firm investing in the intersection of life science, engineering, and computation. Over her career she has led the execution of dozens of equity investments and business deals. Rowan currently serves as an independent director at Natera, Inc. (NTRA), Cambridge Innovation Capital, Cellanome and CornerstoneAI. Previously she was regional Head of Johnson Johnson Innovation, Head of Healthcare Investing at GE Ventures and Head of Precision Diagnostics at GE Healthcare. Rowan was a partner at MDV for over a decade, investing in a wide variety of data-enabled companies including Adamas (IPO:ADMS), Pacific Biosciences (IPO:PACB), ParAllele Biosciences (Acq:AFFX), Personalis (IPO:PSNL), Sequenta (Acq:ADPT) and Verinata (Acq:ILMN). She was an early employee at Rosetta (IPO Acq:MRK) and Incyte (INCY) and is a co-founder of Initiate Studios. Rowan holds a PhD in Biochemistry from the University of Cambridge and carried out post-doctoral research at UCSF.

---

Talk
Atul Butte Company Competition Finals Judge
NA

AI and Data Sciences Showcase:
BEVC
Early-stage venture capital enabling exceptional founders. Focus at the intersection of life sciences, engineering, and computation.

Cathryn Cadwell

Biography
Cathryn Cadwell leads a research program at UCSF dedicated to understanding the cellular architecture and circuit logic of the human cerebral. Her lab integrates single-cell genomics, electrophysiology, viral circuit mapping, human primary tissue and organoid models to uncover how cortical neurons develop, connect, and malfunction in neurological disorders. Dr. Cadwell pioneered innovative technologies such as Patch-seq, enabling multimodal characterization of single neuron morphology, physiology and gene expression. More recently, she has advanced scalable, sequencing-based approaches to connectomics using barcoded viral tools to link molecular cell types to circuit function. By combining human models with cutting-edge computational and experimental tools, she aims to reveal the cellular and circuit-level mechanisms underlying epilepsy. Her groups interdisciplinary approach bridges fundamental neuroscience, human biology, and translational insight, with the goal of informing next-generation strategies to restore healthy brain function.

---

Talk
Precision Pipelines: Accelerating Epilepsy Translation with DataJoint
Discover how the Cadwell Lab (UCSF) leverages DataJoint to power translational research for drug-resistant epilepsy. Learn how automated precision pipelines aim to unify multi-scale dataspanning single-cell genomics, physiology, morphology, and circuit models of human tissueto accelerate the development of novel regenerative cell therapies.

AI and Data Sciences Showcase:
UCSF
Cadwell Lab at UCSF deciphers human cortical cell types and circuits to map how diverse neurons assemble, connect, and malfunction in health and disease.

Asaf Zviran

Biography
Dr. Zviran is an experienced entrepreneur, scientist, and executive with over 20 years of experience in the defense and life science industries. Dr. Zviran co-founded C2i Genomics, where he served as both CEO and CSO. He guided the company from its beginnings as an academic spin-off to a globally recognized industry leader, culminating in a successful exit. Currently, Dr. Zviran is the co-founder and CEO of Prism AI Therapeutics, an AI-driven multi-omics CDxDx management company. Additionally, Asaf co-chair the Multi-Omics AI working group at the BLOODPAC non-profit organization.

---

Talk
Multi-omics AI-driven DxCDx development from small clinical cohorts
Prism AIs platform utilizes our proprietary multi-tensor spectral decomposition method to transform complex multi-omics data from early phase clinical trials into mechanistically interpretable and clinically actionable models, as well as drug efficacy and toxicity biomarkers. Our goal is to improve drug development success rates and expand the patient population that can access precision medicine.

AI and Data Sciences Showcase:
Prism AI Therapeutics
Prism AI is revolutionizing the development and management of multi-omics Diagnostic (Dx) and Companion Diagnostic (CDx) assets. Using an AI-first approach and global SaaS-like business model that can span clinical trials through commercialization, our goal is to enable the development of next-generation therapies and biomarkers.

Dimitri Yatsenko

Biography
Dimitri Yatsenko is the scientific lead behind DataJoint, an open-source framework widely adopted across neuroscience for building reproducible, scalable, and fully automated data pipelines. Originally developed during his work at Baylor College of Medicine, DataJoint has become foundational infrastructure for labs generating large-scale electrophysiology, imaging, behavioral, and multimodal datasets. Dimitris work focuses on transforming fragmented research workflows into unified, auditable systems that integrate data acquisition, analysis, and computational modeling. Over more than a decade, he has championed data-centric research practices that accelerate discovery, improve scientific rigor, and enable collaborative, multi-institution neuroscience projects. His contributions have helped establish best practices for managing complex experimental data and have empowered researchers to connect raw measurements to higher-order insight with speed, transparency, and reproducibility.

---

Talk
Precision Pipelines: Accelerating Epilepsy Translation with DataJoint
Discover how the Cadwell Lab (UCSF) leverages DataJoint to power translational research for drug-resistant epilepsy. Learn how automated precision pipelines aim to unify multi-scale dataspanning single-cell genomics, physiology, morphology, and circuit models of human tissueto accelerate the development of novel regenerative cell therapies.

AI and Data Sciences Showcase:
Datajoint Inc.
DataJoint is a research-data platform that transforms fragmented lab workflows into automated, reproducible, and scalable data pipelines, enabling faster, reliable scientific discovery across modalities.

Rahul Deo

Biography
Rahul Deo is a cardiologist and scientist with 15+ years of experience in academic medicine, most recently at the University of California, San Francisco, and Harvard Medical School, prior to co-founding Atman Health. He completed a PhD in Biophysics and postdoctoral training in Artificial Intelligence and trained in Internal Medicine at Brigham and Womens Hospital and Cardiology at Massachusetts General Hospital. His focus, both in academia and now at Atman Health, has been to bring technology to improve care, recognizing that a solution will require a deep understanding of both the biological complexity of the underlying diseases and the process of clinical management. He recognizes that the core of the problem is a fundamentally broken provider workflow that has resisted innovation, permitting marginal improvements, but no changes that will impact quality, access, or costs. He co-founded Atman Health to build a new model.

---

Talk
Artificial intelligence-powered specialty care for scaling, complexity, and quality.
Despite significant investment, the same problems remain in healthcare: high costs, poor quality, and limited access. Our software, validated in high-risk populations, redefines the clinical process by using LLM-based clinical data ingestion to feed a transparent, deterministic decision-making engine. Downstream tasks are all automated, enabling outstanding outcomes in a fraction of the time.

AI and Data Sciences Showcase:
Atman Health
Atman Health’s mission is to transform specialty care through artificial intelligence-powered software that enables high-quality, high-complexity care in a fraction of the time.

Arya Khokhar

Biography
Arya Khokhar, founder of Eos AI, is building the essential data infrastructure layer for reliable healthcare AI. Driven by firsthand experience of seeing millions of dollars in AI research fail to reach the clinic due to data drift, her work is focused on solving data-level generalization failures. Her mission is to make fragmented, heterogeneous medical data usable across hospitals, pharma, and research, ensuring AI systems work reliably in real clinical environments.She has led research across medical imaging, multimodal learning, and clinical data harmonization, collaborating with academic medical centers and industry partners to deploy AI systems that translate beyond single institutions. Aryas work bridges research and production, emphasizing reliability, cost reduction, and trust in healthcare AI. Her mission is to make healthcare AI-native by fixing the data foundation beneath models rather than repeatedly retraining them.

---

Talk
Billing to Biomarkers: Making AI That Works
AI models trained on fragmented healthcare data often fail in deployment, eroding clinician trust and slowing scientific discovery. This talk explains why current approaches don't scale, and how fixing data upstream enables reliable downstream models for drug discovery and care delivery, reducing costs, accelerating experimentation, and improving care.

AI and Data Sciences Showcase:
Eos AI
Eos AI is the data infrastructure layer that makes healthcare AI reliable in the real world. By standardizing medical images and clinical text across institutions, we enable downstream models for drug discovery, clinical decision support, billing optimization, and long-term quality-of-care improvement.

Shiva Nathan

Biography
Shiva Nathan is the founder of Onymos, a Silicon Valleybased software company building intelligent automation solutions for healthcare and life sciences. Before founding Onymos, Shiva was Head of Intuits Platforms Services organization. He has also held technical leadership positions at Oracle and CA. These companies continue to leverage the products he helped define and build. He is an alumnus of BITS Pilani and UC Berkeleys Haas School of Business.

---

Talk
The Cost of Manual Work in Automated Labs
Labs automated the instruments, not the workflows around them. This session examines how and why manual document processing persists inside automated labs, from specimen accessioning to billing. It also shows how Onymos DocKnow closes that automation gap by extracting, validating, and analyzing structured and unstructured document data.

AI and Data Sciences Showcase:
Onymos
Onymos is building innovative automation software for the high-trust, high-stakes environments inside healthcare and life sciences. It helps organizations modernize their workflows and unlock the value of unstructured data without ever compromising security, compliance, or control.

Mike Polcari

Biography
Mike is the founder of Haplotype Labs.Previously, Mike served as the VP Chief Architect at 23andMe. Mike's tenure at 23andMe spanned a 15+ year category-defining journey from Series A through IPO and beyond.Prior to 23andMe, Mike was an early engineer at Salesforce.com and developed technology at Merrill Lynch.Mike holds a BS in CS from Cornell, a MS in Biomedical Informatics from Stanford, and multiple patents related to cloud computing, security, genetics, and machine learning.

---

Talk
HaploHub: The AI First EHR for Multi-omic Precision Health
As a community, we are advancing our understanding how our systems, organs, tissues, and cell types deteriorate with age. Precision prevention increasingly depends on large 'omics profiles of each individual. We are building a shared EHR to store and interpret the 'omics cloud and invite each of you to contribute to it.

AI and Data Sciences Showcase:
Haplotype Labs
Haplotype Labs helps precision medicine organization predict detect and prevent disease using polygenic risk scores and multi-omic AI models.

Cristian Tomasetti

Biography
Cristian Tomasetti, Ph.D., is director of the Center for Cancer Prevention, Early Detection and Monitoring at City of Hope, director of the Division of Mathematics for Cancer Evolution and Early Detection in the Department of Computational and Quantitative Medicine at Beckman Research Institute of City of Hope, and professor and director of the Division of Integrated Cancer Genomics at Translational Genomics Research Institute (TGen).Dr. Tomasetti is recognized internationally for his paradigm-shift contributions to the current understanding of cancer etiology and tumor evolution. By combining mathematical modeling, statistical analysis, and machine learning with experimental, epidemiological and DNA sequencing data, he has provided the first quantitative evidence for the significant role in cancer causation played by the normal, e.g., endogenous, accumulation of somatic mutations in the cells of the human body. As an applied mathematician, he currently leads the effort to develop novel blood tests and classification artificial intelligence algorithms for the early detection of cancer and monitoring of cancer patients.Before joining City of Hope and TGen, he was an associate professor of Oncology and Biostatistics at Johns Hopkins University with appointments in the Division of Biostatistics and Bioinformatics, in both the Department of Oncology (Sidney Kimmel Comprehensive Cancer Center) and the Department of Biostatistics (Bloomberg School of Public Health). Dr. Tomasetti holds a Ph.D. in applied mathematics from the University of Maryland, College Park (December 2010). After his Ph.D., he was a Ruth L. Kirschstein National Research Service Award Postdoctoral Fellow in the Department of Biostatistics at the Harvard School of Public Health and the Department of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute (January 2011 through June 2013), after which he became a faculty member at Hopkins (assistant professor, July 2013 through December 2017).

AI and Data Sciences Showcase:
City of Hope